Aclaris Therapeutics' stock jumps on positive data for drug developed by St. Louis-based unit

The drug was developed by St. Louis-based Aclaris Life Sciences Inc., formerly Confluence Life Sciences Inc., which Aclaris acquired in 2017.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.